Drug R&D is changing. About time.

Worldwide Pharma R&D Spend

Drug discovery used to be a linear, trial-and-error-based process. Now it is precision engineering. That means better clinical candidates are generated, faster. Human trials remain a development mainstay, but streamlined site selection, protocol design and recruitment – plus optimized molecules – may boost speed and success rates in the clinic too. This matters, because the […]

Obesity Keeps Setting the Pace for Pharma Growth

Evaluate Spotlight_metabolic

Obesity has grown faster than any other therapy area over the past seven years, at more than 50% a year, and is forecast to lead again to 2033 at around 13%. Metabolic disease sales are on course to rise from around $260 billion in 2022 to roughly $730 billion in 2033. In the latest Evaluate […]

Three things we learned in our 2027 drug launches webinar

2027 Drug launches

20 potential launches, 11 therapy areas and 15 new drug classes. Our recent webinar, Key Potential Drug Launches in 2027: Expert Webinar, covered all of it. Evaluate’s expert analysts, Piotr Lis and Niru Ibeanu, took us through the drugs most likely to move markets next year, from the five value leaders to gene therapies, oncolytic […]

Why analysts aren’t covering your biotech company

Why analysts aren't covering your biotech company

A sell-side analyst tells a small or mid-cap healthcare company they are interested. The science is compelling, the data look promising, and management is accessible. Then nothing happens. The initiation report never comes. The cause is usually economics, and understanding this changes how a company approaches the path to biotech analyst coverage. The cost of […]

The healthcare coverage gap is a valuation gap

The healthcare coverage gap

There are more than a thousand publicly traded healthcare companies on US exchanges alone. Globally, hundreds more are listed on the LSE, Euronext, and exchanges across Asia-Pacific. Together they represent trillions of dollars in market value, thousands of clinical programs, and some of the most consequential innovation happening anywhere in the economy. A significant number […]

Cardiovascular sales set to grow 11% a year as new leaders emerge

Evaluate Spotlight, Series One, Episode 4: Cardiovascular. With Mary Anderson, Senior Consultant, and Jessica Merrill, Senior Editor. 10 to 20 minutes, on demand.

The branded cardiovascular market is forecast to grow at 11% a year between 2025 and 2032, well ahead of the 7% forecast for prescription drugs overall. That growth is fueled through new products across novel mechanisms and modalities, and the 2032 ranking of leading companies will look very different from today’s. Scrip’s Jessica Merrill and […]

Advice to biotech leaders: forecasting for launch

Andrew Ward discussing forecasting for launch

As a biotech approaches commercial launch, the forecast often still carries the shape it was given in the early days: built by finance, before a commercial team existed. In this video, I explain why adding a commercial perspective as launch nears is critical. In the past I’ve seen companies drawing on a client forecast that […]

Evaluate Leaders Forum: Pipeline productivity, over breakfast, in London

Evaluate Leaders Forum, 17 November 2026, 8:00 AM to 10:00 AM, Charing Cross, London, UK

Most people in pharma are aware that R&D costs are rising, both in dollar terms and in development timelines. But the reaction is less well-known: risk is being front loaded to Phase I and relative success rates have fallen by around 15%. More promisingly, the average launch fares better today, now sitting at $1.6bn after […]

Inside the $200 Billion Race for the Next Immunology Blockbusters

Evaluate Spotlight, Series One, Episode 3: New Targets, New Modalities, New Leaders. With Helena Kelly, Consultant, and Melanie Senior, Healthcare Analyst. 23 minutes, on demand.

Immunology is one of pharma’s most valuable and fastest-growing therapy areas, with forecast compound annual growth of over 9% and anticipated combined sales of $200 billion by 2032. Multi-indication immunology blockbusters dominate the landscape across more than 100 autoimmune and inflammatory conditions, many sharing underlying biological mechanisms. That “pipeline-in-a-product” profile appeals strongly to companies managing […]

CNS Dealmaking has Become More Selective

Evaluate Spotlight - central nervous system

CNS drug development has had a significant revival. Anti-amyloid agents like Leqembi have shown meaningful slowing of Alzheimer’s progression, and Cobenfy’s 2024 approval marked the first non-dopaminergic schizophrenia treatment in over 30 years. A therapeutic area that saw multiple big pharma exits just a decade ago is attracting capital again. We cover the full picture […]